ABT · 10-Q · 2026Q3 · Full report
Order Backlog and Book-to-Bill
ABBOTT LABORATORIES · 2026-11-04 · Importance 38 · Surprise 24 · In source text
As of September 30, 2026, Abbott reported approximately $6.2 billion of estimated future revenue from unsatisfied or partially unsatisfied performance obligations in its Diagnostic Products segment. These obligations primarily reflect future product sales under contracts with minimum purchase obligations, extended warranties or services for previously sold equipment, and remote monitoring services for previously implanted devices. Abbott excludes obligations related to contracts with original expected durations of one year or less from this disclosure.
Key facts
- Abbott expected to recognize revenue on approximately $6.2 billion of remaining performance obligations in the Diagnostic Products segment as of September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +40.5% | Abbott expected to recognize revenue on approximately $6.2 billion of remaining performance obligations in the Diagnostic Products segment… |